These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8137947)

  • 1. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type-1 envelope glycoprotein.
    Benjouad A; Mabrouk K; Gluckman JC; Fenouillet E
    FEBS Lett; 1994 Mar; 341(2-3):244-50. PubMed ID: 8137947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Rochat H; Montagnier L; Bahraoui E
    J Virol; 1992 Apr; 66(4):2473-83. PubMed ID: 1347797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of synthetic peptides corresponding to various epitopes of the human immunodeficiency virus envelope protein.
    Zaghouani H; Hall B; Shah H; Bona C
    Adv Exp Med Biol; 1991; 303():53-62. PubMed ID: 1725238
    [No Abstract]   [Full Text] [Related]  

  • 6. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
    Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
    Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    Lu S; Wyatt R; Richmond JF; Mustafa F; Wang S; Weng J; Montefiori DC; Sodroski J; Robinson HL
    AIDS Res Hum Retroviruses; 1998 Jan; 14(2):151-5. PubMed ID: 9462925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
    Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
    Kelker HC; Schlesinger D; Valentine FT
    J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
    Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
    Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates.
    Boudet F; Lasarte JJ; Sarobe P; Borras-Cuesta F; Theze J
    AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1671-9. PubMed ID: 8959242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
    Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1.
    Levi M; Rudén U; Birx D; Loomis L; Redfield R; Lövgren K; Akerblom L; Sandström E; Wahren B
    J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):855-64. PubMed ID: 8315572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.